New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children

Future Oncology

Volumn 2, Issue 5, 2006, Pages 675-685

  Gupta, Abha A ^a   Pappo, Alberto S ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Nonrhabdomyosarcomatous soft tissue sarcoma; Novel therapies; Rhabdomyosarcoma; Xenograft

Indexed keywords

BORTEZOMIB; CEFIXIME; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLAVOPIRIDOL; GEFITINIB; GEMCITABINE; IMATINIB; IMMUNOGLOBULIN G; IRINOTECAN; IXABEPILONE; LEFLUNOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; OBLIMERSEN; PROTEIN BCL 2; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMSIROLIMUS; TIPIFARNIB; TOPOTECAN; TRABECTEDIN; UNINDEXED DRUG; VINCRISTINE;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG FATALITY; DRUG RECEPTOR BINDING; DRY SKIN; ELECTROLYTE DISTURBANCE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HUMAN; HYPOKALEMIA; HYPOTENSION; INFECTION; MEDICAL SPECIALIST; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; RECURRENT CANCER; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SOMNOLENCE; THROMBOCYTOPENIA; TUMOR XENOGRAFT; VOMITING;

ANIMALS; CAMPTOTHECIN; CHILD; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE I; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; RHABDOMYOSARCOMA; SARCOMA; SURVIVAL RATE; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 33750045991     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.5.675     Document Type: Review

References (82)

1. National Cancer Institute SEER Program: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Ries LAG, Smith MA, Gurney JG et al. (Eds). NIH Pub No 99-4649. Bethesda MD. USA (1999).
2. Pappo AS, Shapiro DN, Crist WM, Maurer HM: Biology and therapy of pediatric rhabdomyosarcoma. J. Clin. Oncol. 13, 2123-2139 (1995).
3. Crist WM, Anderson JR, Meza JL et al.: Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol. 19, 3091-3102 (2001).
4. Breneman JC, Lyden E, Pappo AS et al.: Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 21, 78-84 (2003).
5. Carli M, Colombatti R, Oberlin O et al.: European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J. Clin. Oncol. 22, 4735-4742 (2004).
6. Weigel BJ, Breitfeld PP, Hawkins D. Crist WM, Baker KS: Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J. Pediatr. Hematol. Oncol. 23, 272-276 (2001).
7. Spunt SL, Smith LM, Ruymann FB et al.: Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Clin. Cancer Res. 10. 6072-6079 (2004).
8. Pappo AS, Lyden E, Breneman J et al.: Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. J. Clin. Oncol. 19, 213-219 (2001).
9. Houghton PJ, Adamson PC, Blaney S et al.: Testing of new agents in childhood cancer preclinical models: meeting summary. Clin. Cancer Res. 8, 3646-3657 (2002).
10. Houghton PJ, Stewart CF, Thompson J, Santana VM, Furman WL, Friedman HS: Extending principles learned in model systems to clinical trials design. Oncology 12, 84-93 (1998).
11. Furman WL, Stewart CF, Poquette CA et al.: Direct translation of a protracted irinotecan schedule from a xenograft model to a Phase I trial in children. J. Clin. Oncol. 17, 1815-1824 (1999).
12. Hazelton BJ, Houghton JA, Parham DM et al.: Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res. 47. 4501-4507 (1987).
13. Houghton JA, Cook RL, Lutz PJ, Houghton PJ: Childhood rhabdomyosarcoma xenografts: responses to DNA-interacting agents and agents used in current clinical therapy. Eur. J. Cancer Clin. Oncol. 20, 955-960 (1984).
14. Pappo AS, Lyden E, Breitfeld P et al.: Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma (RMS): a Phase II window trial from the Soft Tissue Sarcoma Committee (STS) of the Children's Oncology Group (COG). Presented at: the American Society Clinical Oncology. Orlando, FL. USA 18-21 May 2002.
15. Rodriguez-Galindo C, Radomski K, Stewart CF, Furman W, Santana VM, Houghton PJ: Clinical use of topoisomerase I inhibitors in anticancer treatment. Med. Pediatr. Oncol. 35, 385-402 (2000).
16. Houghton PJ, Cheshire PJ, Hallman JD et al.: Efficacy of topoisomerase I inhibitors topotecan and irinotecan administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36, 393-403 (1995).
17. Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ. Wharam MD, Meyer WH: Efficacy of topotecan and cyclophosphamide given in a Phase II window trial in children with newly diagnosed metastatic rhabdomyo-sarcoma: a Children's Oncology Group Study. J. Clin. Oncol. 22, 1398-1403 (2004).
18. Blaney SM, Balis FM. Cole DE et al.: Pediatric Phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 53, 1032-1036 (1993).
19. Blaney SM, Needle MN, Gillespie A et al.: Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch National Cancer Institute and Children's Cancer Group Study. Clin. Cancer Res. 4, 357-360 (1998).
20. Blaney SM, Phillips PC, Packer RJ et al.: Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 78, 527-531 (1996).
21. Hawkins DS, Bradfield S, Whitlock JA et al.: Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer (2006) (Epub ahead of print).
22. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C: Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II study. J. Pediatr. Hematol. Oncol. 20, 315-318 (1998).
23. Saylors RL, Stine KC, Sullivan J et al.: Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II study. J. Clin. Oncol. 19, 3463-3469 (2001).
24. Thompson J, George EO, Poquette CA et al.: Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin. Cancer Res. 5, 3617-3631 (1999).
25. Furman WL, Crews KR, Billups C et al.: Cefixime allows greater dose escalation of oral irinotecan: a Phase I study in pediatric patients with refractory solid tumors. J. Clin. Oncol. 24, 563-570 (2006).
26. Casanova M, Ferrari A, Spreafìco, F et al.: Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 94, 3263-3268 (2002).
27. Kuttesch JF, Krallo MD, Bleyer WA, Reaman GH: Phase II evaluation of vinorelbine in recurrent pediatric malignancies. Presented at: the American Society Clinical Oncology. Orlando, FL, USA 18-21 May 2005.
28. Casanova M, Ferrari A, Bisogno G et al.: Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 101, 1664-1671 (2004).
29. Peterson JK, Tucker C, Favours E et al.: In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative against pediatric cancer models. Clin. Cancer Res. 11, 6950-6958 (2005).
30. Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4, 335-348 (2004).
31. Hosoi H, Dilling MB, Shikata T et al.: Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 59, 886-894 (1999).
32. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A: Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 4, 1533-1540 (2005).
33. Spunt SL, Poquette CA, Hurt YS et al.: Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J. Clin. Oncol. 17, 3697-3705 (1999).
34. Pratt CB, Pappo AS, Gieser P et al.: Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group study. J. Clin. Oncol. 17, 1219 (1999).
35. Pappo AS, Devidas M, Jenkins J et al.: Phase II trial of neoadjuvant vincristine ifosfamide and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group study. J. Clin. Oncol. 23, 4031-4038 (2005).
36. Pratt CB, Maurer HM, Gieser P et al.: Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery irradiation and chemotherapy: a Pediatric Oncology Group study. Med. Pediatr. Oncol. 30, 201-209 (1998).
37. Spunt SL, Hill DA, Motosue AM et al.: Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. J. Clin. Oncol. 20, 3225-3235 (2002).
38. Carli M, Ferrari A, Mattke A et al.: Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J. Clin. Oncol. 23, 8422-8430 (2005).
39. Albritton KH, Randall RL: Prospects for targeted therapy of synovial sarcoma. J. Pediatr. Hematol. Oncol. 27, 219-222 (2005).
40. Badros AZ, Goloubeva O, Rapoport AP et al.: Phase II study of G3139, a Bc1-2 antisense oligonucleotide in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J. Clin. Oncol. 23, 4089-4099 (2005).
41. Joyner DE, Albritton KH, Bastar JD, Randall RL: G3139 antisense oligonucleotide directed against antiapoptotic Bc1-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. J. Orthop. Res. 24, 474-480 (2006).
42. Altander SV, Illei PB, Chen Y et al.: Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2. and ELF3 with epithelial differentiation. Am. J. Pathol. 161, 1587-1595 (2002).
43. Lynch TJ, BD, Sordella R, Gurubhagavatula S et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
44. Bode B, Frigerio S, Behnke S et al.: Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod. Pathol. 19, 541-547 (2006).
45. Daw NC, Furman WL, Stewart CF et al.: Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group study. J. Clin. Oncol. 23, 6172-6180 (2005).
46. Miller SJ. Rangwala F, Williams J et al.: Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res. 66, 2584-2591 (2006).
47. Ling BC, Wu J. Miller SJ et al.: Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 7, 65-75 (2005).
48. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787-2799 (2003).
49. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 17, 3631-3652 (1999).
50. Widemann BC, Salzer WL, Arceci RJ et al.: Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis Type I and plexiform neurofibromas. J. Clin. Oncol. 24, 507-516 (2006).
51. Zewail-Foote M, Hurley LH: Ecteinascidin-743: a minor groove alkylator that bends DNA toward the major groove. J. Med. Chem. 42, 2493-2497 (1999).
52. Minuzzo M, Marchini S. Broggini M, Faircloth G, D'Incalci M, Mantovani R: Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc. Natl Acad. Sci. US4 97, 6780-6784 (2000).
53. Jin S, Gorfajn B. Faircloth G, Scotto KW: Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl Acad. Sci. USA 97, 6775-6779 (2000).
54. Le Cesne A, Blay JY, Judson I et al.: Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23, 576-584 (2005).
55. Yovine A, Riofrio M, Blay JY et al.: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol. 22, 890-899 (2004).
56. Garcia-Carbonero R, Supko JG, Manola J et al.: Phase II and pharmacokinetic study of ecteinascidin-743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol. 22, 1480-1490 (2004).
57. Schoffski P, Huygh G, Clement P et al.: Tumor control and objective responses: single center experience with ecteinascidin-743 (ET-743, Yondelis), an active compound for the treatment of patients with advanced soft tissue and bone sarcomas. Presented at: the American Society Clinical Oncology,. Orlando, FL, USA 18-21 May 2005.
58. Van Glabbeke M, Verweij J, Judson I, Nielsen OS: Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38, 543-549 (2002).
59. Verweij J: Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas? J. Clin. Oncol. 23, 5420-5423 (2005).
60. Garcia-Carbonero R, Supko JG, Maki RG et al.: Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J. Clin. Oncol. 23, 5484-5492 (2005).
61. Lau L, Supko JG, Blaney S et al.: A Phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin. Cancer Res. 11, 672-677 (2005).
62. Jordan MA, Wilson L: Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253-265 (2004).
63. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51, 6110-6117 (1991).
64. Blaney SM, Seibel NL, O'Brien M et al.: Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch National Cancer Institute and Children's Cancer Group trial. J. Clin. Oncol. 15, 1538-1543 (1997).
65. Seibel NL, Blaney SM, O'Brien M et al.: Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch National Cancer Institute and Children's Cancer Group trial. Clin. Cancer Res. 5, 733-737 (1999).
66. Zwerdling T, Krailo M, Monteleone P et al.: Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. Cancer (2006) (Epub ahead of print).
67. Reid JM, Qu W, Safgren SL et al.: Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J. Clin. Oncol. 22, 2445-2451 (2004).
68. Leu KM, Ostruszka LJ, Shewach D et al.: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J. Clin. Oncol. 22, 1706-1712 (2004).
69. Hensley ML, Maki R, Venkatraman E et al.: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol. 20, 2824-2831 (2002).
70. Houghton JA, Meyer WH, Houghton PJ: Scheduling of vincristine: drug accumulation and response of xenografts of childhood rhabdomyosarcoma determined by frequency of administration. Cancer Treat Rep. 71, 717-721 (1987).
71. Houghton JA, Cook RL, Lutz PJ, Houghton PJ: Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep. 69, 91-96 (1985).
72. Bisogno G, Riccardi R, Ruggiero A et al.: Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 106, 703-707 (2006).
73. Adamson PC, Blaney SM, Widemann BC et al.: Pediatric Phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU 101. Cancer Chemother. Pharmacol. 53, 482-488 (2004).
74. Bond M, BM, Pappo A, Schultz KR et al.: Phase 2 trial of imatinib mesylate (IM) for treatment or recurrent or refractory pediatric solid tumors: a Children's Oncology Group Study. Presented at: the American Society Clinical Oncology. Orlando, FL, USA 18-21 May 2005.
75. Furman W, Daw NC, Crews KR et al.: A Phase I study of Gefitinib and irinotecan (IRN) in pediatric patients with refractory solid tumors. Presented at: the American Society Clinical Oncology. Orlando, FL. USA 18-21 May 2005.
76. Blaney SM, Bernstein M, Neville K et al.: Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J. Clin. Oncol. 22, 4804-4809 (2004).
77. Fox E, Widemann B, Chen C et al.: Pediatric Phase I trial and pharmacokinetic study of p-glycoprotein inhibitor tariquidar in combination with doxorubicin vinorelbine or docetaxel. Presented at: the American Society Clinical Oncology. New Orleans, MS, USA May 17-18 2004.
78. Rheingold S, Blayney S, Hogarty M et al.: A Phase I trial of G3139 (bc1-2 antisense) combined with cytotoxic chemotherapy in relapsed solid tumors. A Children's Oncology Group Study. Presented at: the American Society Clinical Oncology. Orlando, FL, USA 18-21 May 2005.
79. George RE, Adamson PC, Blayney SM et al.: A Phase I stduy of deciabine (DCT) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in the treatment of relapsed or refractory solid tumors: a Children's Oncology Group Study. American Society of Clinical Oncology. Orlando. FL, USA (2005).
80. Widemann BC, Goodspeed WJ, Goodwin A et al: Phase I trial of epothilone B analog BMS0247550 (ixabepilone) in children with refractory solid tumors. American Society of Clinical Oncology. Orlando, FL USA (2005).
81. Wagner LM, Crews KR, Iacono LC et al.: Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin. Cancer Res. 10, 840-848 (2004).
82. Aquino VM, Weltman SD, Winick NJ et al.: Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study. J. Clin. Oncol. 22, 1413-1419 (2004)